◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › C › CERS

Cerus Corporation (CERS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-10-02

Cerus Corporation (CERS) operates in the MEDICAL DEVICES industry and is headquartered in Concord, United States with about 261 employees. Its market capitalization is roughly $472 million. In the fiscal year ended 2025-12-31, CERS reported $206M in revenue and ($16M) in net income.

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety.

Interactive charts & full statements → Open the CERS valuation workbench →

CERS Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$222M	$206M	$180M	$156M	$162M	$131M	$92M	$75M	$61M	$44M	$37M	$34M	$37M	$40M	$37M	$33M	$23M	$18M	$17M	$11M	$36M
Gross Profit	$116M	$112M	$100M	$86M	$87M	$67M	$51M	$41M	$29M	$21M	$17M	$11M	$15M	$17M	$16M	$15M	$11M	$5M	$7M	$6M	$34M
Gross Margin %	52.2%	54.5%	55.2%	55.2%	53.8%	51.5%	55.2%	55.2%	48.1%	48.3%	45.4%	31.4%	42.0%	43.0%	43.8%	43.9%	47.9%	30.0%	41.4%	52.7%	95.7%
Operating Income (EBIT)	($2M)	($9M)	($14M)	($30M)	($34M)	($49M)	($58M)	($66M)	($55M)	($58M)	($61M)	($61M)	($44M)	($28M)	($17M)	($16M)	($16M)	($24M)	($31M)	($43M)	($9M)
Operating Margin %	-0.9%	-4.2%	-7.9%	-19.2%	-21.0%	-37.4%	-63.5%	-88.7%	-90.3%	-132.1%	-165.3%	-178.5%	-121.5%	-71.4%	-47.1%	-48.2%	-69.1%	-132.5%	-184.9%	-390.9%	-26.6%
Net Income	($7M)	($16M)	($21M)	($37M)	($43M)	($54M)	($60M)	($71M)	($58M)	($61M)	($63M)	($56M)	($39M)	($43M)	($16M)	($17M)	($17M)	($24M)	($29M)	($45M)	($5M)
Net Margin %	-3.1%	-7.6%	-11.6%	-24.0%	-26.4%	-41.5%	-65.1%	-95.4%	-94.5%	-139.1%	-169.2%	-163.2%	-105.7%	-109.3%	-43.4%	-51.4%	-73.2%	-134.2%	-176.8%	-410.2%	-13.4%
EBITDA	$3M	($6M)	($10M)	($26M)	($31M)	($46M)	($55M)	($64M)	($54M)	($52M)	($58M)	($56M)	($37M)	($42M)	($14M)	($15M)	($15M)	($23M)	($29M)	($43M)	($4M)
Earnings Per Share (EPS)	$-0.03	$-0.08	$-0.11	$-0.21	$-0.24	$-0.32	$-0.37	$-0.51	$-0.44	$-0.56	$-0.62	$-0.58	$-0.50	$-0.64	$-0.29	$-0.35	$-0.42	$-0.69	$-0.90	$-1.42	$-0.17
Shares Outstanding (M)	201M	191M	185M	180M	177M	171M	164M	140M	132M	108M	102M	97M	77M	68M	55M	48M	40M	35M	32M	32M	29M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CERS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$57M	$54M	$58M	$53M	$52M	$43M	$51M	$46M
Gross Profit	$30M	$28M	$30M	$28M	$29M	$25M	$27M	$26M
Gross Margin %	51.4%	52.0%	51.5%	53.4%	55.2%	58.8%	53.9%	56.9%
Operating Income (EBIT)	($2M)	$0M	($1M)	$1M	($3M)	($6M)	($1M)	($1M)
Operating Margin %	-3.2%	-0.7%	-1.1%	2.4%	-6.5%	-13.5%	-2.9%	-2.1%
Net Income	($3M)	($2M)	($2M)	$0M	($6M)	($8M)	($3M)	($3M)
Net Margin %	-5.1%	-3.1%	-3.8%	-0.0%	-10.9%	-17.8%	-5.0%	-6.4%
EBITDA	($1M)	$1M	$0M	$3M	($3M)	($5M)	$0M	$0M
Earnings Per Share (EPS)	$-0.01	$-0.01	$-0.01	$-0.00	$-0.03	$-0.04	$-0.01	$-0.02
Shares Outstanding (M)	201M	194M	192M	192M	191M	187M	185M	185M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CERS Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$2M	$5M	$11M	($43M)	($26M)	($34M)	($42M)	($65M)	($31M)	($52M)	($54M)	($51M)	($40M)	($27M)	($14M)	($16M)	($14M)	($15M)	($35M)	($37M)	($15M)
Capital Expenditures (CapEx)	$4M	$3M	$3M	$5M	$2M	$1M	$2M	$9M	$1M	$0M	$1M	$1M	$2M	$1M	$0M	$0M	$2M	$0M	$1M	$1M	$1M
Free Cash Flow (FCF)	($2M)	$3M	$9M	($48M)	($28M)	($35M)	($43M)	($74M)	($32M)	($53M)	($54M)	($52M)	($42M)	($27M)	($14M)	($16M)	($16M)	($15M)	($36M)	($38M)	($16M)
FCF Margin %	-0.9%	1.5%	4.7%	-30.6%	-17.0%	-26.6%	-47.2%	-99.7%	-53.2%	-120.7%	-145.5%	-151.5%	-114.8%	-69.2%	-38.1%	-47.8%	-68.5%	-82.6%	-216.5%	-345.0%	-44.4%
Dividends Paid	—	—	—	$10M	$4M	—	—	—	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CERS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($3M)	($3M)	$6M	$2M	($2M)	($1M)	$5M	$4M
Capital Expenditures (CapEx)	$1M	$0M	$1M	$2M	$0M	$0M	$1M	$1M
Free Cash Flow (FCF)	($4M)	($3M)	$5M	$0M	($3M)	($1M)	$4M	$3M
FCF Margin %	-6.2%	-6.1%	8.5%	0.2%	-5.6%	-2.2%	7.8%	7.3%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

CERS Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$205M	$222M	$201M	$198M	$218M	$237M	$221M	$166M	$163M	$98M	$103M	$139M	$82M	$83M	$49M	$45M	$48M	$34M	$47M	$78M	$116M
Cash & Cash Equivalents	$18M	$20M	$20M	$12M	$36M	$49M	$37M	$35M	$29M	$14M	$23M	$71M	$23M	$29M	$27M	$25M	$29M	$17M	$10M	$20M	$46M
Total Liabilities	$134M	$157M	$144M	$144M	$150M	$152M	$118M	$108M	$79M	$59M	$46M	$45M	$40M	$41M	$30M	$27M	$24M	$13M	$13M	$18M	$15M
Total Debt (Short + Long-Term)	$68M	$87M	$86M	$82M	$72M	$71M	$50M	$46M	$30M	$42M	$19M	$20M	$20M	$3M	$8M	$7M	$5M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$70M	$64M	$56M	$53M	$68M	$85M	$104M	$57M	$85M	$39M	$58M	$95M	$42M	$43M	$19M	$18M	$24M	$21M	$34M	$60M	$101M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive CERS viewer.

Other Companies in MEDICAL DEVICES

AVR · Anteris Technologies Global Corp. Common Stock — $545 million
SGHT · Sight Sciences Inc — $513 million
SENS · Senseonics Holdings, Inc. Common Stock — $503 million
DCTH · Delcath Systems Inc — $500 million
SSII · SS Innovations International Inc. Common Stock — $467 million
BWAY · Brainsway Ltd — $449 million
NPCE · Neuropace Inc — $422 million
OFIX · Orthofix Medical Inc — $369 million

← CERA All “C” companies CERT →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.